What is Cognition Therapeutics Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cognition Therapeutics's operating assets for the quarter that ended in Mar. 2024 was $4.18 Mil. Cognition Therapeutics's operating liabilities for the quarter that ended in Mar. 2024 was $8.96 Mil. Cognition Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $35.16 Mil. Therefore, Cognition Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.14.
Cognition Therapeutics Scaled Net Operating Assets Historical Data
The historical data trend for Cognition Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cognition Therapeutics Scaled Net Operating Assets Chart
|
Cognition Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
-7.30 |
-8.11 |
-0.48 |
- |
-0.08 |
|
Cognition Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
-0.04 |
-0.04 |
-0.08 |
-0.11 |
-0.14 |
Competitive Comparison of Cognition Therapeutics's Scaled Net Operating Assets
For the Biotechnology subindustry, Cognition Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cognition Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Cognition Therapeutics's Scaled Net Operating Assets falls into.
Cognition Therapeutics Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Cognition Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (5.241 | - | 9.451) | / | 50.425 |
| = | -0.08 |
where
Cognition Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Mar. 2024 ) |
| = | (Operating Assets (Q: Mar. 2024 ) | - | Operating Liabilities (Q: Mar. 2024 )) | / | Total Assets (Q: Dec. 2023 ) |
| = | (4.18 | - | 8.957) | / | 35.163 |
| = | -0.14 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cognition Therapeutics (Cognition Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Executives
| John Brendan Doyle |
officer: Chief Financial Officer |
C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494 |
| Lisa Ricciardi |
director, officer: CEO & President |
C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
| Anthony Caggiano |
officer: Chief Medical Officer |
C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
| Ellen B Richstone |
director |
C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886 |
| Fletcher Aaron G.l. |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Leslie W. Kreis |
director, 10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Equity Partners Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Memory Spv Ii, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Iii Nt, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii Qp, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Equity Partners Ii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Bios Fund Iii, Lp |
10 percent owner |
1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107 |
| Peggy Wallace |
director |
C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577 |
| Bios Fund Ii Nt, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
| Bios Fund Ii Qp, Lp |
10 percent owner |
1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107 |
Cognition Therapeutics (Cognition Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CGTX has been successfully added to your